Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Abatacept
Clinical response
Retention
Rheumatoid arthritis
Serostatus
bDMARD
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
27
02
2023
accepted:
25
05
2023
revised:
17
05
2023
medline:
10
8
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
The ASCORE study on treatment for rheumatoid arthritis (RA) showed better retention and clinical response rates for abatacept as first-line versus later-line therapy. This post hoc analysis of ASCORE assessed 2-year retention, efficacy, and safety of subcutaneous (SC) abatacept in Germany, Austria, and Switzerland. Adults with RA who initiated SC abatacept 125 mg once weekly were assessed. Primary endpoint was abatacept retention rate at 2 years. Secondary endpoints: proportions of patients with low disease activity (LDA)/remission per Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (≤ 3.2), Simplified Disease Activity Index (≤ 11), and Clinical Disease Activity Index (≤ 10). Outcomes were analyzed by treatment line and serostatus. For the pooled cohort, the 2-year abatacept retention rate was 47.6%; retention was highest in biologic-naïve patients (50.5% [95% confidence interval 44.9, 55.9]). Patients seropositive for both anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF; + / +) at baseline had a higher 2-year abatacept retention rate than patients with single seropositivity for either APCA or RF or double-seronegativity (- / -), irrespective of treatment line. At 2 years, a higher proportion of patients who were biologic-naïve were in LDA/remission than patients with one or ≥ two prior biologics. A higher proportion of patients with + / + RA (compared with - / - RA) had abatacept retention after 2 years. Early identification of patients with seropositive RA may facilitate a precision-medicine approach to RA treatment, leading to a higher proportion of patients in LDA/remission. NCT02090556; date registered: March 18, 2014 (retrospectively registered). Key Points • This post hoc analysis of a German-speaking subset of European patients with RA from the global ASCORE study (NCT02090556) showed that retention of SC abatacept within this subset was 47.6%, with good clinical outcomes after 2 years. • Patients with double-seropositive RA (ACPA and RF positive) had higher retention of abatacept than patients with double-seronegative RA (ACPA and RF negative). Retention and clinical responses were highest for patients who were biologic-naïve compared with patients who had one or ≥ two prior biologic treatments. • These real-world data may be useful for clinicians in informing individualized treatment pathways for patients with RA, and fostering superior disease control and clinical outcomes.
Identifiants
pubmed: 37314665
doi: 10.1007/s10067-023-06649-x
pii: 10.1007/s10067-023-06649-x
pmc: PMC10412468
doi:
Substances chimiques
Abatacept
7D0YB67S97
Antirheumatic Agents
0
Banques de données
ClinicalTrials.gov
['NCT02090556']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2321-2334Informations de copyright
© 2023. The Author(s).
Références
Smolen J, Aletaha D, McInnes I (2016) Rheumatoid arthritis. Lancet 388:2023–2038
doi: 10.1016/S0140-6736(16)30173-8
pubmed: 27156434
Katchamart W, Koolvisoot A, Aromdee E, Chiowchanwesawakit P, Muengchan C (2015) Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol Int 35:1693–1699. https://doi.org/10.1007/s00296-015-3271-8
doi: 10.1007/s00296-015-3271-8
pubmed: 25903353
van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949-958. https://doi.org/10.1186/ar1767
doi: 10.1186/ar1767
pubmed: 16207336
pmcid: 1257421
Alemao E, Bao Y, Weinblatt ME, Shadick N (2020) Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. Arthritis Care Res (Hoboken) 72:176–183. https://doi.org/10.1002/acr.24071
doi: 10.1002/acr.24071
pubmed: 31529682
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581
doi: 10.1002/art.27584
pubmed: 20872595
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millan I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108–1123. https://doi.org/10.1002/art.41752
doi: 10.1002/art.41752
pubmed: 34101376
Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699. https://doi.org/10.1136/annrheumdis-2019-216655
doi: 10.1136/annrheumdis-2019-216655
pubmed: 31969328
Malmstrom V, Catrina AI, Klareskog L (2017) The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol 17:60–75. https://doi.org/10.1038/nri.2016.124
doi: 10.1038/nri.2016.124
pubmed: 27916980
Bristol Myers Squibb (2020) Orencia (abatacept) prescribing information. https://packageinserts.bms.com/pi/pi_orencia.pdf . Accessed 09/02/2021
Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le BM, Dougados M (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547–554
doi: 10.1136/ard.2007.074773
pubmed: 17921185
Kremer JM, Peterfy C, Russell AS, Emery P, Abud-Mendoza C, Sibilia J, Becker J-C, Westhovens R, Genant HK (2014) Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. J Rheumatol 41:1077–1087
doi: 10.3899/jrheum.130263
pubmed: 24786925
Westhovens R, Kremer J, Emery P, Russell A, Alten R, Barre E, Dougados M (2014) Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 32:553–562
pubmed: 25005467
Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R (2018) Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. J Rheumatol 45:1085–1092. https://doi.org/10.3899/jrheum.170344
doi: 10.3899/jrheum.170344
pubmed: 29657147
Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C III, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R (2011) Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheumatol 63:2854–2864
doi: 10.1002/art.30463
Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM (2017) Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 36:1395–1400. https://doi.org/10.1007/s10067-017-3587-8
doi: 10.1007/s10067-017-3587-8
pubmed: 28255739
Alten R, Mariette X, Lorenz HM, Nusslein H, Galeazzi M, Navarro F, Chartier M, Heitzmann J, Poncet C, Rauch C, Le Bars M (2019) Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clin Rheumatol 38:1413–1424. https://doi.org/10.1007/s10067-019-04449-w
doi: 10.1007/s10067-019-04449-w
pubmed: 30790095
Alten R, Mariette X, Flipo RM, Caporali R, Buch MH, Patel Y, Marsal S, Sanmarti R, Nurmohamed MT, Griffiths H, Peichl P, Bannert B, Chartier M, Connolly SE, Lozenski K, Rauch C (2022) Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clin Rheumatol. https://doi.org/10.1007/s10067-022-06176-1
doi: 10.1007/s10067-022-06176-1
pubmed: 35536413
pmcid: 9287226
Alten R, Mariette X, Buch M, Caporali R, Flipo R-M, Forster A, Nurmohamed M, Patel Y, Peichl P, Sanmarti R, Chartier M, Heitzmann J, Rauch C, Connolly S (2019) ASCORE, a 2-year, observational, prospective multicentre study of subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice: 1-year interim analysis. Ann Rheum Dis 78(Suppl 2):1639 (Abstract AB0361)
Alten R, Mariette X, Buch M, Caporali R, Flipo R-M, Forster A, Nurmohamed M, Patel Y, Peichl P, Sanmarti R, Chartier M, Heitzmann J, Rauch C, Connolly SE (2018) Experience with subcutaneous abatacept in routine clinical practice: 6-month interim analysis of a 2-year, prospective, non-interventional, multicentre study in patients with RA. Ann Rheum Dis 77(Suppl 2):1392 (Abstract AB0461)
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413
doi: 10.1136/ard.2011.149765
pubmed: 21292833
Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X, French Society of R, the investigators participating in Air ORA, registries R (2019) Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ 364:l67. https://doi.org/10.1136/bmj.l67
doi: 10.1136/bmj.l67
pubmed: 30679233
pmcid: 6344892
Okazaki S, Watanabe R, Harigae H, Fujii H (2020) Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis. Tohoku J Exp Med 250:153–159. https://doi.org/10.1620/tjem.250.153
doi: 10.1620/tjem.250.153
pubmed: 32132324
Mariette X, Schaeverbeke T, Gaudin P, Chartier M, Heitzmann J, Vannier-Moreau V, Hilliquin P, Cantagrel A (2019) Two-year abatacept retention rate in clinical practice in the French ACTION cohort. Joint Bone Spine 86:753–759. https://doi.org/10.1016/j.jbspin.2019.07.006
doi: 10.1016/j.jbspin.2019.07.006
pubmed: 31352138
Peichl P, Alten R, Galeazzi M, Lorenz HM, Nusslein H, Navarro F, Elbez Y, Chartier M, Hackl R, Rauch C, Connolly SE (2020) Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study. Wien Med Wochenschr 170:132–140. https://doi.org/10.1007/s10354-019-00710-8
doi: 10.1007/s10354-019-00710-8
pubmed: 31654156
Choy E, Groves L, Sugrue D, Hurst M, Houghton J, Venkatachalam S, Patel YI, Maxwell JR, Pollock KG, Henning S (2021) Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatol 5:3. https://doi.org/10.1186/s41927-020-00173-0
doi: 10.1186/s41927-020-00173-0
pubmed: 33536080
pmcid: 7857859
Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nusslein HG, Chartier M, Elbez Y, Rauch C, Le Bars M (2017) Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open 3:e000538. https://doi.org/10.1136/rmdopen-2017-000538
doi: 10.1136/rmdopen-2017-000538
pubmed: 29435360
pmcid: 5761291
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K, Chartier M, Poncet C, Rauch C, Le BM (2016) Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol 34:489–499
pubmed: 26966919
Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhao H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European registry analysis. Arthritis Rheumatol 68:1346–1352. https://doi.org/10.1002/art.39595
doi: 10.1002/art.39595
pubmed: 26815727
Liu P-C, Ssu C-T, Tsao Y-P, Liou T-L, Tsai C-Y, Chou C-T, Chen M-H, Leu C-M (2020) Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells. Arthritis Res Ther 22:64. https://doi.org/10.1186/s13075-020-2138-x
doi: 10.1186/s13075-020-2138-x
pubmed: 32228715
pmcid: 7106629
Alten R, Feist E, Lorenz HM, Nusslein H, Voll RE, Chartier M, Elbez Y, Rauch C (2019) Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. Clin Rheumatol 38:3049–3059. https://doi.org/10.1007/s10067-019-04648-5
doi: 10.1007/s10067-019-04648-5
pubmed: 31300979